Topic Hub
8 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 8 of 8 clinical reviews.
Evidence-based protocols for identifying, grading, and managing adverse events associated with DPP-4 inhibitors (sitagliptin, saxagliptin, linagliptin, alogliptin) in type 2 diabetes.
Read clinical reviewA prescriber-level guide to DPP-4 inhibitor pharmacology, place in T2D therapy, formulary strategy, prior-authorization requirements, and denial appeals, with trial data, dosing tables, and step-edit navigation.
Read clinical reviewA clinician-level monograph covering the DPP-4 inhibitor drug class: mechanism, pharmacokinetics, CV outcomes trials, renal dosing, place in therapy, and prescribing guidance for sitagliptin, saxagliptin, linagliptin, alogliptin, and vildagliptin.
Read clinical reviewA clinician-level review of DPP-4 inhibitor pharmacology, drug-drug interactions, dosing, and safety, with a full DDI table for sitagliptin, saxagliptin, alogliptin, and linagliptin.
Read clinical reviewA prescriber-level guide to the monitoring bundle for DPP-4 inhibitors (gliptins), covering baseline labs, follow-up intervals, renal dose adjustments, and safety surveillance for sitagliptin, saxagliptin, linagliptin, and alogliptin.
Read clinical reviewA prescriber-level review of DPP-4 inhibitors across special populations: renal impairment, heart failure, elderly patients, pregnancy, hepatic disease, and more. Includes dosing tables, trial data, and guideline citations.
Read clinical reviewA board-reviewed, MD/PharmD-level guide to DPP-4 inhibitor dosing, titration, renal adjustment, combination use, and safe tapering. Includes original decision framework, trial data, and guideline citations.
Read clinical reviewA prescriber-level guide to choosing between sitagliptin, saxagliptin, alogliptin, linagliptin, and trelagliptin based on renal function, cardiac history, drug interactions, and cost.
Read clinical review